There are two components to the supply of IGIV (or any plasma-derived product): collection and processing. BAX is in good shape on the processing end, and collections are relatively easy to expand by simply opening new collection centers. This 2009 NYT article is a good read: http://www.nytimes.com/2009/12/06/business/06plasma.html .
If Gammagard for AD makes it to market, BAX will presumably make an offer to competing plasma companies that is too good to refuse :- )
Market Data 
Markets 
AI
